Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab (Xolair) for allergic bronchopulmonary aspergillosis in cystic fibrosis
2007-006648-23Phase 4Terminated
- Sponsor
- Novartis
- Start
- Aug 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in cystic fibrosis (CF) and allergic bronchopulmonary aspergillosis (ABPA) comparing Omalizumab (Xolair) with Placebo (2 arms). Primary endpoint: Primary efficacy of Xolair in CF with ABPA. Started Aug 2008; status: terminated.
02
Drugs
omalizumab
03
Conditions
cystic fibrosis (CF)allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on 2007-006648-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006648-23.